InterVenn
InterVenn Biosciences operates an AI-powered glycoproteomics platform that combines proprietary neural networks with mass spectrometry to enable blood-based liquid biopsy diagnostics and biomarker discovery, primarily serving clinicians, women's-health practices, health systems, and biopharma research collaborators.
- Company typePrivate
- Founded2017
- HeadquartersSouth San Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What InterVenn does
InterVenn Biosciences (legally Venn Biosciences Corporation) operates a proprietary AI-powered glycoproteomics platform that combines high-resolution mass spectrometry with custom neural networks to decode complex glycan signatures associated with disease. The company's core engine, branded GlycoVision, is trained on what InterVenn describes as the largest clinically annotated glycoproteomic dataset in the world, and is used to automate glycopeptide identification, scoring, and biomarker discovery across oncology, autoimmune, and infectious disease indications. Layered on top of GlycoVision is the GlycoKnow™ diagnostic franchise, beginning with GlycoKnow™ Ovarian, a CLIA-validated laboratory-developed blood test that assesses malignancy risk in women with documented adnexal masses prior to surgery; the test is performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory in South San Francisco.
The company makes money on three axes. First, it sells GlycoKnow™ Ovarian as an LDT on a quote-based, pay-as-you-go basis to clinicians and women's-health practices through select clinical partners and early access programs; the test is not currently eligible for insurance reimbursement. Second, it offers collaborative biomarker discovery and validation services to biopharma and academic research partners using the GlycoVision engine, executed on serum or plasma samples. Third, it leverages a multi-year distribution partnership with Aranscia — embedding the test into Spesana, 2bPrecise, and AccessDx Laboratory platforms — to reach health systems, oncology, and women's health providers at scale.
The company is privately held and venture-backed, having raised approximately $244M across four rounds including a $201M Series C led by SoftBank Group in August 2021. Leadership is headed by CEO Andrew Quong, with COO David A. King (ex-Standard Biotools), CLO Nicholas S. Khadder, and scientific advisors Carolyn Bertozzi (Stanford, HHMI, 2022 Nobel laureate) and Carlito B. Lebrilla (UC Davis). InterVenn has 51-100 employees, operates primarily from South San Francisco with a London investor presence, and is currently commercializing through a sales-led GTM that combines direct clinical-lab sales, channel partnerships, and event-driven demand generation (e.g., SITC 2026).
InterVenn firmographics
Firmographics- Name
- InterVenn
- Legal name
- Venn Biosciences Corporation
- Website
- https://intervenn.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- InterVenn Biosciences operates an AI-powered glycoproteomics platform that combines proprietary neural networks with mass spectrometry to enable blood-based liquid biopsy diagnostics and biomarker discovery, primarily serving clinicians, women's-health practices, health systems, and biopharma research collaborators.
- Ownership category
- akta.pro rank
InterVenn industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)
Keywords
Where InterVenn is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
InterVenn business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- GlycoKnow™ Ovarian LDT Sales: Revenue generated by selling GlycoKnow™ Ovarian as a laboratory-developed test (LDT) through select clinical partners and early access programs. Specimen-based clinical testing performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory. Test is not currently eligible for insurance reimbursement (per stated intended use disclosure).
- Discovery & Validation Services via GlycoVision: Service offering for research partners to outsource discovery or validation cohorts using the GlycoVision engine, including study design, sample processing (serum/plasma), and data interpretation end-to-end.
- Clinical Workflow Integration & Commercial Partnerships: Multi-year partnership with Aranscia to commercialize GlycoKnow™ Ovarian via Aranscia's Spesana, 2bPrecise, and AccessDx Laboratory platforms — embedding InterVenn's liquid biopsy into health system clinical workflows.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | GlycoKnow™ Ovarian LDT — pricing not publicly disclosed |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels5 records
InterVenn product offering
Product offeringCore offering
InterVenn Biosciences develops and commercializes an AI-powered glycoproteomics platform (GlycoVision) that combines high-resolution mass spectrometry with proprietary neural networks to decode the glycoproteome for biomarker discovery and clinical diagnostics. Its flagship commercial product is GlycoKnow™ Ovarian, a first-of-its-kind blood-based laboratory-developed test (LDT) that uses AI-decoded glycopeptide signatures to assess malignancy risk in women with adnexal masses prior to surgery, performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory. The company also offers collaborative glycoproteomic biomarker discovery and validation services to research partners across oncology, autoimmune, and infectious disease indications.
Product overview
InterVenn Biosciences offers a platform-plus-modules architecture centered on its proprietary GlycoVision AI engine, which automates mass-spectrometry-based glycoproteomic analysis using proprietary neural networks trained on the world's largest clinically annotated glycoproteomic dataset. Layered on top of GlycoVision is the GlycoKnow™ diagnostic franchise — beginning with GlycoKnow™ Ovarian, a CLIA-validated laboratory-developed blood test that uses the platform's AI decoding of glycopeptide signatures to assess malignancy risk in women with adnexal masses — together with collaborative biomarker discovery services that feed new clinical indications and modules (e.g., endometriosis, response-to-ICI, NSCLC, melanoma, RCC, pancreatic, breast, and autoimmune/infectious disease) into the same underlying engine.
Differentiator
Problem solved
Functional benefit
Brands
- GlycoKnow™: A blood-based laboratory-developed test (LDT) that analyzes the glycoproteome to aid in the assessment of adnexal masses for ovarian cancer risk. GlycoKnow™ Ovarian is the lead product in this line.
- GlycoVision
Products and services
- GlycoKnow™ Ovarian A first-of-its-kind AI-driven, blood-based liquid biopsy laboratory-developed test (LDT) that analyzes the glycoproteome to aid clinicians (gynecologic oncologists, women's health specialists) in assessing malignancy risk in women 18+ with a documented adnexal mass prior to surgery. It provides an adjunct likelihood-of-malignancy assessment to inform triage and surgical planning, and is performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory on serum or plasma specimens.
- GlycoVision Proprietary AI-powered platform for high-throughput glycoproteomic analysis that combines advanced mass spectrometry with machine learning algorithms, custom neural networks trained for glycopeptide identification and scoring, and a large clinically annotated glycoproteomic database. It automates and scales biomarker discovery and is the underlying engine on which GlycoKnow™ diagnostic tests and collaborative research services are built; offered to research and biopharma partners as a discovery and validation platform.
- InterVenn Glycoproteomic Biomarker Discovery & Validation Service End-to-end collaborative glycoproteomics service for academic and biopharma research partners, spanning study design, sample processing (serum or plasma), and data analysis/interpretation using the GlycoVision engine. Supports both discovery profiling and targeted approaches, and enables discoveries to be transferred to InterVenn's CLIA lab environment. Applicable across oncology, autoimmune, and infectious disease indications.
Quantifiable outcome
- 17 peer-reviewed publications in glycoproteomics across oncology, autoimmune, and infectious disease
- +3 more outcomes
Companies that use InterVenn
Customer profileSegments4 records
Ideal customer profiles3 records
InterVenn technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature6 records
InterVenn partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Society for Immunotherapy of Cancer (SITC)coreInterVenn is participating in the SITC Annual Meeting in Phoenix, AZ (Nov 4-8, 2026) — a key conference channel for engaging the immuno-oncology community around its immune checkpoint inhibitor biomarker work.
- AransciaflagshipMulti-year agreement to accelerate commercialization of the GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test. Aranscia contributes its software suite (Spesana, 2bPrecise, AccessDx Laboratory) and laboratory resources to expand clinical workflows and availability across women's health, oncology, and health system care settings. Aimed at democratizing access to precision diagnostics for ovarian cancer.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
InterVenn competitors and assessment
Company assessmentDirect peers
- Freenome: Multiomics liquid biopsy company developing blood-based colorectal cancer screening and other early-detection assays using AI on proteomic and genomic signals. Comparable to InterVenn's platform-plus-diagnostic architecture using AI/mass spectrometry over blood samples.
- SomaLogic: Proteomics platform company operating SomaScan high-plex protein measurement and developing diagnostic applications. Directly comparable to InterVenn as an AI-driven protein/glycoprotein biomarker discovery platform feeding into clinical diagnostic products.
- GRAIL: Multi-cancer early detection liquid biopsy company pursuing population-scale blood-based screening. Comparable to InterVenn as a blood-based, AI-driven cancer detection platform targeting adnexal mass triage and other early-cancer use cases.
- Natera: Commercial cell-free DNA diagnostics company with oncology and women's health franchises including Signatera and Empower. Comparable to InterVenn's blood-based diagnostic model and its women's-health/oncology go-to-market strategy.
- Oncocyte: Commercial molecular diagnostics company with oncology-focused tests (e.g., DetermaRx, VitaGraft) pursuing reimbursement and clinical adoption. Comparable to InterVenn as a small-cap oncology diagnostics company; Mitch Levine previously served as Oncocyte's CFO before joining InterVenn's board.
- Seer: Proteomics platform company commercializing a nanoparticle-enhanced mass spectrometry workflow for deep, unbiased proteomic profiling. Closely comparable to InterVenn's mass-spectrometry-plus-AI architecture and its claim to a large proprietary annotated dataset feeding biomarker discovery.
- Guardant Health: Leading commercial liquid biopsy company with oncology-focused blood tests for tumor profiling and minimal residual disease. Directly comparable to InterVenn as a blood-based cancer diagnostics franchise pursuing non-invasive oncology workflows through CLIA/CAP lab operations.
Broad incumbents
- Myriad Genetics: Diversified molecular diagnostics company with hereditary cancer, oncology, and women's health franchises. Comparable to InterVenn's clinical cancer diagnostics go-to-market and women's-health positioning; Alec Ford previously led at Myriad before joining InterVenn's board.
- Exact Sciences: Established cancer diagnostics leader (Cologuard, Oncotype DX) pursuing multi-cancer liquid biopsy via the Cancerguard program. A broad incumbent overlapping InterVenn's blood-based, AI-augmented oncology diagnostic ambition and reimbursement strategy.
Emerging players
- BillionToOne: Commercial molecular diagnostics company with a prenatal liquid biopsy franchise (Unity) and an oncology liquid biopsy program (Northstar). Comparable as a private/commercial-stage liquid biopsy company with a women's-health oncology focus similar to GlycoKnow™ Ovarian.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
InterVenn social profiles
Digital presenceInterVenn compliance and trust
Trust signalCompliance5 records
InterVenn financial estimates
Financial estimateRevenue estimate
Valuation estimate
InterVenn leadership team
Management profileNumber of profiles
Profiles9 records
InterVenn subsidiaries and ownership
Company hierarchySubsidiaries1 record
InterVenn funding detail
Funding detailFunding overview
Funding rounds4 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InterVenn M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InterVenn
What does InterVenn do?
InterVenn Biosciences develops and commercializes an AI-powered glycoproteomics platform (GlycoVision) that combines high-resolution mass spectrometry with proprietary neural networks to decode the glycoproteome for biomarker discovery and clinical diagnostics. Its flagship commercial product is GlycoKnow™ Ovarian, a first-of-its-kind blood-based laboratory-developed test (LDT) that uses AI-decoded glycopeptide signatures to assess malignancy risk in women with adnexal masses prior to surgery, performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory. The company also offers collaborative glycoproteomic biomarker discovery and validation services to research partners across oncology, autoimmune, and infectious disease indications.
Is InterVenn a public or private company?
InterVenn is a private company. It is classified as venture growth investor backed and is currently operating.
When was InterVenn founded?
InterVenn was founded in 2017. It employs 101 to 250 people.
Where is InterVenn based?
InterVenn is headquartered in South San Francisco, United States, in the North America region.
How does InterVenn make money?
Three revenue lines are on record. GlycoKnow™ Ovarian LDT Sales are the primary driver. The others are discovery & Validation Services via GlycoVision and clinical Workflow Integration & Commercial Partnerships.
Who are InterVenn's main competitors?
Direct peers on record are Freenome, SomaLogic, GRAIL, Natera, Oncocyte, Seer and Guardant Health. Broad incumbents are Myriad Genetics and Exact Sciences. BillionToOne is listed as an emerging player.
Does InterVenn have an API?
No public API is recorded for InterVenn.
What industry is InterVenn in?
InterVenn's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 8731.